Samsung Invests $110 Million in GRAIL to Bring Multi-Cancer Blood Test to Asia
核心洞察
Samsung C&T (搜索) and Samsung Electronics (搜索) announced a $110 million strategic investment in GRAIL, a US biotechnology company developing AI-powered early cancer detection technology.
GRAIL's Galleri (搜索) test can detect approximately 50 types of cancer through a single blood test and has accumulated 400,000 testing records since its 2021 launch.
Samsung C&T (搜索) secured exclusive distribution rights for Korea and plans expansion to Singapore and Japan, while Samsung Electronics (搜索) will integrate GRAIL's technology with its Samsung Health platform.
Samsung C&T (搜索) and Samsung Electronics (搜索) announced a $110 million strategic investment in GRAIL, an American biotechnology company pioneering AI-powered early cancer detection through blood testing. The investment marks Samsung's significant expansion into the precision diagnostics sector and establishes the Korean conglomerate as a key partner for bringing multi-cancer screening technology to Asian markets.
Revolutionary Multi-Cancer Detection Technology
GRAIL has developed technology that can optimally select microscopic DNA (搜索) fragments related to cancer among hundreds of millions of DNA fragments in the blood and analyze them with AI-based dielectric data technology. This approach enables the system to predict not only the presence of cancer but also determine the anatomical location of tumors.
The company's flagship product, Galleri (搜索), can detect approximately 50 types of cancer early with a single blood test. Since its commercial launch in 2021, the test has accumulated approximately 400,000 testing records and is currently being evaluated in large-scale clinical trials with the National Health Service (NHS) in the United Kingdom.
Strategic Market Expansion in Asia
Through this investment, Samsung C&T (搜索) has secured exclusive distribution rights for the Galleri (搜索) test in Korea. The company plans to extend its partnership with GRAIL to Singapore and Japan, positioning Samsung as the primary gateway for multi-cancer screening technology across key Asian markets.
"Starting with Korea, we have formed a partnership with Samsung to provide multiple cancer early diagnosis services in Asia," said Harpal Kumar, president of GRAIL's overseas business. "Samsung's investment will greatly help achieve major milestones for the insurance coverage of gallery inspections in the United States and major markets."
Technology Integration and Digital Health Platform
Samsung Electronics (搜索) plans to leverage this partnership to enhance its digital health capabilities by integrating GRAIL's technology and accumulated gene-based early cancer diagnosis data with the Samsung Health platform. This integration aims to provide users with innovative healthcare experiences through personalized digital health services.
Park Heon-soo, head of Samsung Electronics (搜索)' MX division's digital health team, stated, "We will strive to provide a personalized digital health experience by incorporating Grail's clinical genetic data and technology into Samsung Electronics' digital health platform."
Regulatory Pathway and Market Outlook
GRAIL is preparing to submit its Galleri (搜索) test for approval to the US Food and Drug Administration (FDA) sometime next year, representing a critical milestone for the company's commercial expansion. The FDA approval process will be crucial for establishing the test's credibility and enabling broader market adoption.
Samsung's Broader Healthcare Investment Strategy
This investment represents part of Samsung's comprehensive healthcare investment strategy through its Life Science Fund, which was jointly established with Samsung BioLogics and Samsung Bioepis. The fund has previously invested in C2N (搜索), a US-based blood-based Alzheimer's test technology company, and Flagship Pioneering 8 fund.
Samsung Electronics (搜索) has also made strategic acquisitions in the healthcare sector, recently investing in Element Bioscience (搜索), an American DNA (搜索) analysis equipment company, and acquiring Xealth (搜索), an American digital healthcare company.
Kim Jae-woo, vice president of Samsung C&T (搜索)'s Life Science business, commented, "Through this investment and strategic cooperation, Samsung C&T has provided an opportunity to expand Samsung C&T's bio and healthcare investment portfolio into the technology sector where genes and AI are fused."